Mounjaro and Zepbound Heartburn: A Dietitian's Guide to Eating on Tirzepatide
Short answer: Heartburn and indigestion are more common on tirzepatide (Mounjaro and Zepbound) than on placebo, but in the trials they were mostly mild to moderate and showed up mainly during dose increases. For most people, how you eat in the evening matters most: a smaller, earlier dinner and no food in the three hours before bed.
In this post
How is tirzepatide different from Ozempic?
How common is heartburn on Mounjaro or Zepbound?
Mounjaro vs Ozempic: which is easier on reflux?
Why it's often worse at night, and the evening plan
Dose increases: what to expect and what to tell your prescriber
The takeaway
If you search "Mounjaro acid reflux," most of what comes up is written about GLP-1s in general, or about Ozempic. This post is about tirzepatide specifically: the numbers from its own trials, the pattern around dose increases, and a plan for the time of day when it tends to hit hardest.
That last part comes straight from my practice. The complaint I hear most from clients on Mounjaro and Zepbound is nighttime heartburn. That's an observation from the people I work with, not a statistic, but it shapes how I build their plans, and it shapes this post.
How is tirzepatide different from Ozempic?
Mounjaro and Zepbound are both tirzepatide. Mounjaro is the diabetes brand and Zepbound is the weight-loss brand. Ozempic and Wegovy are semaglutide, which acts on one hormone receptor (GLP-1). Tirzepatide is a dual agonist: it acts on the GLP-1 receptor and on a second one, the GIP receptor. Both medications slow how quickly your stomach empties, which is the main reason reflux can show up. For the semaglutide research, read my post on Ozempic and acid reflux, and for the basics across all of these medications, start with my full GLP-1 and reflux guide.
How common is heartburn on Mounjaro or Zepbound?
A 2025 joint advisory from four nutrition and obesity medicine organizations summarized the side effects reported in the tirzepatide obesity trials. At the 15 mg dose, compared with placebo:
Dyspepsia (indigestion): 10% on tirzepatide vs 4% on placebo
GERD: 5% vs 2%
Eructation (burping): 5% vs 1%
These match Zepbound's official prescribing information, which pools the two main placebo-controlled obesity trials. So reflux-type symptoms are more common on tirzepatide, and most people in these trials didn't get them.
The largest tirzepatide obesity trial, SURMOUNT-1, followed 2,539 adults. It found that GI side effects were the most common side effects, mostly mild to moderate, and happened primarily during dose escalation, the weeks when the dose is being stepped up.
Some people did stop the medication because of side effects of any kind: 4.3%, 7.1% and 6.2% on the 5, 10 and 15 mg doses, compared with 2.6% on placebo. Most people stayed on it.
Mounjaro vs Ozempic: which is easier on reflux?
This is one of the most common questions I get, and the honest answer is that we don't know yet.
The only head-to-head trial, SURMOUNT-5, randomized 751 adults to tirzepatide or semaglutide, each at the highest dose the person tolerated. It was open-label, meaning participants and researchers knew who was taking which drug. Weight changed by -20.2% on tirzepatide and -13.7% on semaglutide.
For side effects, GI symptoms were the most common in both groups, mostly mild to moderate, and happened during dose escalation. What the trial did not report is a reflux-specific comparison between the two drugs. So there's no evidence yet that either one is easier on reflux.
If you're choosing or switching medications, that conversation belongs with your prescriber. What I can tell you is that the eating strategy below works the same way on either drug, because it targets the same thing: how much food is sitting in your stomach when you lie down.
Why it's often worse at night, and the evening plan
Three things stack up at night on tirzepatide:
Your stomach empties more slowly. A dinner that would have moved along in a few hours may still be there at bedtime.
Gravity stops helping. When you're upright, gravity helps keep stomach contents down. When you lie flat, that help goes away.
Dinner is often the biggest meal. A small appetite during the day can lead to skipped meals, then a larger meal in the evening, right before the longest stretch you'll spend lying down. Evenings are also when many people relax with a glass of wine, and alcohol can make reflux worse.
I explain the full mechanism in why acid reflux gets worse at night. Here's the evening plan I use with clients on Mounjaro and Zepbound.
1. Use the 3-Hour Buffer. No food in the three hours before bed. Beverages are fine. If you go to bed at 10, your last bite is at 7. On a medication that slows stomach emptying, this buffer gives dinner time to move out of your stomach before you lie down.
If you get hungry in that window, have something to drink instead, like water or a caffeine-free herbal tea. If you're hungry most nights, that usually means your earlier meals were too small, so the change to make is earlier in the day.
2. Move your bigger meal earlier. Eat a real breakfast and lunch so you arrive at dinner hungry instead of starving. That makes a smaller dinner much easier to stick with. My GLP-1 sample day shows what that looks like meal by meal.
3. Keep dinner small and protein first. Start with the protein on your plate, keep fat moderate, and stop at comfortable fullness. Fried and very rich dinners keep food in your stomach even longer.
4. Set up your sleep. Your sleeping position and setup matter once the lights go off. I cover the details in how to sleep with acid reflux.
Dose increases: what to expect and what to tell your prescriber
Tirzepatide is started at a low dose and stepped up over time. In both SURMOUNT-1 and SURMOUNT-5, GI side effects happened mainly during those dose increases. In practice, that means a new flare after a dose step is common, and it often settles as your body adjusts.
What to do around each dose step:
Tighten the evening plan for that week. Be strict with the 3-Hour Buffer and keep dinner small.
Write it down. Note when symptoms started, what time of day they happen, and what you ate that evening. The Reflux Clarity Log in the FLORA App tracks symptoms, food, medication, supplements and habits, and its Insights tab is built to bring to appointments.
Tell your prescriber. Share when the heartburn started relative to your dose change, how often it happens, and whether it wakes you up. They can decide whether anything about your plan should change.
Please don't skip, delay or change a dose on your own. That decision belongs to you and your prescriber together.
Call your prescriber sooner if you have trouble swallowing, food that feels stuck, vomiting you can't stop, severe upper-belly pain, black stools or vomiting blood, or if you wake up choking or coughing. The full list is in my Ozempic and acid reflux post.
The takeaway
Heartburn on Mounjaro and Zepbound is more common than on placebo, usually mild, and most likely around dose increases. Nighttime is where most people feel it, so start there: use the 3-Hour Buffer, move your bigger meals earlier in the day, and keep dinner small. Track what happens after each dose step and bring it to your prescriber.
If evenings on Mounjaro or Zepbound have turned into a heartburn routine, our reflux dietitians can build an eating plan around your dose schedule. Apply to work 1:1 at https://www.mollypelletier.com/acid-reflux-specialist. Prefer to start on your own? The Reflux Relief Masterclass walks you through the full framework: https://www.mollypelletier.com/acid-reflux-relief-masterclass.
With love,
Verified Citations
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. SURMOUNT-1, n=2,539. PMID 35658024. https://doi.org/10.1056/NEJMoa2206038
Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). 2025;33(8):1475-1503. Table 2, tirzepatide 15 mg vs placebo. PMID 40445127. https://doi.org/10.1002/oby.24336
Eli Lilly. ZEPBOUND (tirzepatide) injection, Prescribing Information, Table 1, adverse reactions in the pool of two placebo-controlled weight reduction trials (placebo n=958; 15 mg n=941): dyspepsia 10% vs 4%, eructation 5% vs 1%, GERD 5% vs 2%. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36. SURMOUNT-5, open-label, n=751. PMID 40353578. https://doi.org/10.1056/NEJMoa2416394
